Format

Send to

Choose Destination
See comment in PubMed Commons below
Vitam Horm. 2004;67:65-79.

Monoclonal antibodies against TRAIL.

Author information

1
Institute of Cancer Research and Molecular Medicine Norwegian University of Science and Technology, N-7489 Trondheim, Norway.

Abstract

TRAIL (tumor necrosis factor related apoptosis inducing ligand) is a cytokine proposed to be used in cancer therapy, since it kills cancer cells but not normal cells. Also, recent studies report that TRAIL inhibits the development of arthritis. In order to investigate the role of TRAIL in health and disease, monoclonal antibodies against TRAIL have been developed. This chapter gives an overview of different monoclonal antibodies against TRAIL which are published or commercially available. Monoclonal antibodies against TRAIL are useful in different immunological techniques, and this chapter presents an overview of the applications of these antibodies with a focus on immunoassays for detection of soluble TRAIL. In addition, the physiological significance of some results obtained by using monoclonal antibodies against TRAIL are discussed.

PMID:
15110172
DOI:
10.1016/S0083-6729(04)67005-1
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center